ABOS Projected Dividend Yield
Acumen Pharmaceuticals Inc ( NASDAQ : ABOS )Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). Co. is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer's pathology). 20 YEAR PERFORMANCE RESULTS |
ABOS Dividend History Detail ABOS Dividend News ABOS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |